Glatiramer Acetate 40 mg/mL in Relapsing–Remitting Multiple Sclerosis: A Review

New Multiple Sclerosis Phenotypic Classification

(2014) Fred D. Lublin   EUROPEAN NEUROLOGY

Effect of glatiramer acetate three-times weekly on the evolution of new, active multiple sclerosis lesions into T1-hypointense “black holes”: a post hoc magnetic resonance imaging analysis

(2014) Robert Zivadinov et al.   JOURNAL OF NEUROLOGY

Glatiramer Acetate (Copaxone) Modulates Platelet Activation and Inhibits Thrombin-Induced Calcium Influx: Possible Role of Copaxone in Targeting Platelets during Autoimmune Neuroinflammation

(2014) Sarah C. Starossom et al.   PLoS One

Advances in the treatment of relapsing - Remitting multiple sclerosis

(2014) CrisS Constantinescu et al.   Biomedical Journal

Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis

(2013) Omar Khan et al.   ANNALS OF NEUROLOGY

Randomized study combining interferon and glatiramer acetate in multiple sclerosis

(2013) Fred D. Lublin et al.   ANNALS OF NEUROLOGY

Glatiramer Acetate: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis and in Delaying the Onset of Clinically Definite Multiple Sclerosis

(2013) Lesley J. Scott   CNS DRUGS

The pharmacokinetics of glatiramer acetate for multiple sclerosis treatment

(2013) Silvia Messina et al.   Expert Opinion on Drug Metabolism & Toxicology

The mechanism of action of glatiramer acetate in multiple sclerosis and beyond

(2012) Rina Aharoni   AUTOIMMUNITY REVIEWS

Glatiramer Acetate in Treatment of Multiple Sclerosis: A Toolbox of Random Co-Polymers for Targeting Inflammatory Mechanisms of both the Innate and Adaptive Immune System?

(2012) Babak Jalilian et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Multiple sclerosis

(2012) Alyssa Nylander et al.   JOURNAL OF CLINICAL INVESTIGATION

Glatiramer Acetate Increases Phagocytic Activity of Human Monocytes In Vitro and in Multiple Sclerosis Patients

(2012) Refik Pul et al.   PLoS One

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis

(2011) Anne Waschbisch et al.   PLoS One

Impact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosis

(2010) Hiangkiat Tan et al.   ADVANCES IN THERAPY

Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

(2010) Giancarlo Comi et al.   ANNALS OF NEUROLOGY

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

(2010) C. Ford et al.   Multiple Sclerosis Journal

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial

(2009) G Comi et al.   LANCET

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate

(2009) M. Chiarini et al.   Multiple Sclerosis Journal

Efficacy of treatment of MS with IFN -1b or glatiramer acetate by monthly brain MRI in the BECOME study

(2009) D. Cadavid et al.   NEUROLOGY

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1  in human monocytes and multiple sclerosis

(2009) D. Burger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glatiramer Acetate

(2008) François Blanchette et al.   JOURNAL OF NEUROLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY